Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OBP-301 + Pembrolizumab in Advanced Solid Tumors
NCT03172819Phase 1Completed
- Start
- Oct 2017
- Primary completion
- Apr 2021
- Modality
- Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of suratadenoturev in solid tumor (advanced stage). Primary endpoint: Dose Limiting Toxicity at 4 weeks. Started Oct 2017; status: completed.
02
Drugs
suratadenoturev
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03172819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03172819.